If multiple combination products similar to the device constituent marketed outside of the US resulted in reportable malfunction, is it required to provide the details of the combination product in the E2B report?

Yes, FDA recommends that the report for a foreign malfunction identifies each US combination product (using the Similar characterization) for which the malfunction event being reported is relevant.